US Stock MarketDetailed Quotes
RVMD Revolution Medicines
- 57.850
- -0.730-1.25%
Close Nov 29 13:00 ET
- 57.500
- -0.350-0.61%
Post 17:01 ET
9.73BMarket Cap-15806P/E (TTM)
59.350High57.360Low1.19MVolume57.880Open58.580Pre Close69.57MTurnover0.78%Turnover RatioLossP/E (Static)168.22MShares62.40052wk High6.21P/B8.89BFloat Cap23.38052wk Low--Dividend TTM153.65MShs Float62.400Historical High--Div YieldTTM3.40%Amplitude14.080Historical Low58.323Avg Price1Lot Size
About Revolution Medicines Company
Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.
Company Profile
SymbolRVMD
Company NameRevolution Medicines
Listing DateFeb 13, 2020
Issue Price17.00
Founded2004
CEODr. Mark A. Goldsmith, M.D., PhD
MarketNASDAQ
Employees378
Fiscal Year Ends12-31
Address700 Saginaw Drive
CityRedwood City
ProvinceCalifornia
CountryUnited States of America
Zip Code94063
Phone1-650-481-6801
Websitehttp://www.revmed.com
Company Executives
- Name
- Position
- Salary
- Dr. Mark A. Goldsmith, M.D., PhD
- President, Chief Executive Officer and Chairman of the Board
- 10.41M
- Jack Anders
- Chief Financial Officer and Principal Accounting Officer
- 3.05M
- Margaret A. Horn, J.D.
- Chief Operating Officer
- 4.39M
- Dr. Wei Lin
- Chief Medical Officer
- --
- Dr. Mary Pinder-Schenck, M.D.
- Senior Vice President, Head of Medical Affairs
- --
- Dr. Jing Yi, PhD
- Senior Vice President, Head of Program Leadership.
- --
- Jeff Cislini
- Senior Vice President, General Counsel and Secretary
- --
- Xiaolin Wang
- Executive Vice President, Development
- 3.23M
- Ryan Asay
- Senior Vice President, Corporate Affairs
- --
- Dr. Mason Shih, M.D.
- Senior Vice President, Head of Drug Safety
- --
- Dr. Stephen M. Kelsey, F.R.C.P.,M.D.
- President, Research and Development
- 4.39M
- Alexis A. Borisy, A.M.
- Lead Independent Director
- 510.63K
- Dr. Sushil Patel, PhD
- Independent Director
- 475.19K
- Dr. Barbara L. Weber, M.D.
- Independent Director
- 480.19K
- Frank K. Clyburn, Jr
- Independent Director
- --
- Elizabeth McKee Anderson, M.B.A.
- Independent Director
- 483.78K
- Dr. Sandra J. Horning, M.D.
- Independent Director
- 720.00K
- Dr. Flavia Borellini, PhD
- Independent Director
- 489.09K
- Dr. Thilo Schroeder, PhD
- Independent Director
- --
- Dr. Lorence H. Kim, M.D.
- Independent Director
- 489.99K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data